AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30379302 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 290
Study 27712774 — intervention group
Group type: EXPERIMENTAL
Intervention: CTO PCI (early PCI of the CTO)
Number of subjects: 304
Study 27712774 — intervention group
Group type: COMPARATOR
Intervention: No CTO PCI (conservative treatment without PCI of the CTO)
Number of subjects: 304
Study 27712774 — intervention group
Group type: EXPERIMENTAL
Intervention: CTO PCI (in left anterior descending coronary artery subgroup)
Number of subjects: 304
Study 27712774 — intervention group
Group type: COMPARATOR
Intervention: No CTO PCI (in left anterior descending coronary artery subgroup)
Number of subjects: 304
Study 27712774 — intervention group
Group type: EXPERIMENTAL
Intervention: CTO PCI
Number of subjects: 304
Study 27712774 — intervention group
Group type: COMPARATOR
Intervention: No CTO PCI
Number of subjects: 304
Study 25211216 — intervention group
Group type: EXPERIMENTAL
Intervention: MDRS (remote monitoring and control diabetes management system)
Number of subjects: 37
Study 25211216 — intervention group
Group type: COMPARATOR
Intervention: SAP therapy (sensor-augmented pump therapy)
Number of subjects: 37
Study 22854911 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine patch
Number of subjects: 60
Study 22854911 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 60
Study 20458045 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide (IDD-ETC) every 2 weeks
Number of subjects: 1284
Study 20458045 — intervention group
Group type: COMPARATOR
Intervention: Conventionally scheduled chemotherapy with epirubicin/cyclophosphamide followed by paclitaxel every three weeks
Number of subjects: 1284
Study 18545193 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional weight training class (n = 27)
Number of subjects: 79
Study 18545193 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid weight training class (n = 25)
Number of subjects: 79
Study 18545193 — intervention group
Group type: EXPERIMENTAL
Intervention: Online weight training class (n = 27)
Number of subjects: 79
Study 15852994 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane, fentanyl, and thiopental
Number of subjects: 42
Study 15852994 — intervention group
Group type: COMPARATOR
Intervention: Propofol and remifentanil (TIVA group)
Number of subjects: 42
Study 12589345 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (≥0.016 mg/kg of IgE per 4 weeks)
Number of subjects: 525
Study 12589345 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 525
Study 12589345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 525
Study 10547166 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote intercessory prayer (prayer group), n = 466
Number of subjects: 990
Study 10547166 — intervention group
Group type: COMPARATOR
Intervention: Usual care group, n = 524
Number of subjects: 990
Study 8857563 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral (cyclosporine microemulsion preconcentrate)
Number of subjects: 0
Study 8857563 — intervention group
Group type: COMPARATOR
Intervention: Sandimmun (conventional formulation of cyclosporine)
Number of subjects: 0
Study 1825969 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms EE2 and 75 micrograms gestodene (F)
Number of subjects: 83
Study 1825969 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms EE2 and 150 micrograms desogestrel (M)
Number of subjects: 83
Study 1825969 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (F and M)
Number of subjects: 83
Study 6440740 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 20 mcg/day device
Number of subjects: 1509
Study 6440740 — intervention group
Group type: COMPARATOR
Intervention: TCu 380Ag device
Number of subjects: 1509
Study 6440740 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 1509
Study 31707787 — intervention group
Group type: EXPERIMENTAL
Intervention: teen Mental Health First Aid
Number of subjects: 1605
Study 31707787 — intervention group
Group type: COMPARATOR
Intervention: physical first aid
Number of subjects: 1605
Study 30951589 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-based treatment (ABT)
Number of subjects: 189
Study 30951589 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioral treatment (SBT)
Number of subjects: 189
Study 30071866 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer group intervention for HIV prevention and testing
Number of subjects: 432
Study 30071866 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation success measures (e.g., # of peer groups held)
Number of subjects: 432
Study 30071866 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation process and factors related to success
Number of subjects: 432
Study 30071866 — intervention group
Group type: EXPERIMENTAL
Intervention: Effectiveness of the peer group intervention
Number of subjects: 432
Study 30071866 — intervention group
Group type: EXPERIMENTAL
Intervention: Feasibility, acceptability, and sustainability assessments
Number of subjects: 432
Study 27445635 — intervention group
Group type: EXPERIMENTAL
Intervention: Navimed device for self-reporting pain
Number of subjects: 52
Study 27445635 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative pain care
Number of subjects: 52
Study 24646371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready to Act health education programme (n = 322)
Number of subjects: 509
Study 24646371 — intervention group
Group type: COMPARATOR
Intervention: Routine care (n = 187)
Number of subjects: 509
Study 22530979 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Patient and Provider intervention
Number of subjects: 860
Study 22530979 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Only intervention
Number of subjects: 860
Study 22530979 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider Only intervention
Number of subjects: 860
Study 22530979 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (Patient + Provider) intervention
Number of subjects: 860
Study 22530979 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 860
Study 19745172 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 4731
Study 19745172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4731
Study 17664952 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate plus sulfasalazine
Number of subjects: 0
Study 17664952 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate plus chloroquine
Number of subjects: 0
Study 17664952 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate plus cyclosporin
Number of subjects: 0
Study 17664952 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate plus leflunomide
Number of subjects: 0
Study 17664952 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate plus intramuscular gold
Number of subjects: 0
Study 17664952 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate plus doxycycline
Number of subjects: 0
Study 17664952 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple DMARD therapy
Number of subjects: 0
Study 17664952 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate plus hydroxychloroquine
Number of subjects: 0
Study 15023172 — intervention group
Group type: EXPERIMENTAL
Intervention: Botox (50 units)
Number of subjects: 100
Study 15023172 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport (150 units)
Number of subjects: 100
Study 11666125 — intervention group
Group type: EXPERIMENTAL
Intervention: TTFCA 60 mg thrice daily (Group A)
Number of subjects: 62
Study 11666125 — intervention group
Group type: EXPERIMENTAL
Intervention: TTFCA 30 mg thrice daily (Group B)
Number of subjects: 62
Study 11666125 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 62
Study 11666125 — intervention group
Group type: EXPERIMENTAL
Intervention: TTFCA 60 mg thrice daily (Group D - normal subjects)
Number of subjects: 62
Study 9677501 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystallized intelligence (WAIS-R subtests: information, comprehension, similarities)
Number of subjects: 25
Study 9677501 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid intelligence (WAIS-R subtests)
Number of subjects: 25
Study 9677501 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (N=25)
Number of subjects: 25
Study 8305420 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen (CEE) plus 10 mg medroxyprogesterone acetate (MPA)
Number of subjects: 184
Study 8305420 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg CEE plus 5 mg MPA
Number of subjects: 184
Study 8305420 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg CEE only
Number of subjects: 184
Study 8305420 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 184
Study 2729386 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior colporrhaphy
Number of subjects: 107
Study 2729386 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Pereyra procedure
Number of subjects: 107
Study 2729386 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch retropubic urethropexy
Number of subjects: 107
Study 5002115 — intervention group
Group type: EXPERIMENTAL
Intervention: Perhexiline
Number of subjects: 55
Study 5002115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 31102345 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% methimazole
Number of subjects: 50
Study 31102345 — intervention group
Group type: COMPARATOR
Intervention: 4% hydroquinone
Number of subjects: 50
Study 31203243 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise referral schemes enhanced by self-management strategies
Number of subjects: 0
Study 31203243 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised scales (Marcus's Self‐Efficacy Questionnaire, Physical Activity Self‐Regulation Scale, Lubben Social Network Scale)
Number of subjects: 0
Study 31203243 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative and quantitative findings
Number of subjects: 0
Study 27412706 — intervention group
Group type: EXPERIMENTAL
Intervention: LGG‐TMC0356‐fermented milk for 10 weeks
Number of subjects: 25
Study 27412706 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 25
Study 26134881 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement-based care (MBC)
Number of subjects: 304
Study 26134881 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 304
Study 22583681 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal mouthrinse (HM)
Number of subjects: 48
Study 22583681 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil mouthrinse (EO)
Number of subjects: 48
Study 22583681 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse (CHX)
Number of subjects: 48
Study 22583681 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 48
Study 20418523 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A (500 U Dysport) injection
Number of subjects: 24
Study 20418523 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection (saline)
Number of subjects: 24
Study 19473511 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line writing workshop group
Number of subjects: 48
Study 19473511 — intervention group
Group type: COMPARATOR
Intervention: Standard writing guidance training
Number of subjects: 48
Study 16452593 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) exposure
Number of subjects: 15
Study 16452593 — intervention group
Group type: COMPARATOR
Intervention: Air exposure (control)
Number of subjects: 15
Study 15325934 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone administration before myocardial reperfusion
Number of subjects: 80
Study 11465759 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention during cerebral angiography
Number of subjects: 30
Study 11465759 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 30
Study 10193989 — intervention group
Group type: EXPERIMENTAL
Intervention: Gortex membrane (GM)
Number of subjects: 302
Study 10193989 — intervention group
Group type: COMPARATOR
Intervention: Control group (pericardium left open)
Number of subjects: 302
Study 8058353 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen administration (10 subjects)
Number of subjects: 43
Study 8058353 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen administration (12 subjects)
Number of subjects: 43
Study 8058353 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 subjects)
Number of subjects: 43
Study 8058353 — intervention group
Group type: COMPARATOR
Intervention: Control group (9 subjects)
Number of subjects: 43
Study 3190004 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubeless group (subgroup A) - operated on without any NG tube
Number of subjects: 150
Study 3190004 — intervention group
Group type: COMPARATOR
Intervention: Subgroup B - NG tube inserted after induction of anesthesia and removed one hour after the operation
Number of subjects: 150
Study 3190004 — intervention group
Group type: COMPARATOR
Intervention: Subgroup C - NG tube inserted after induction of anesthesia and removed 12 hours after the operation
Number of subjects: 150
Study 808194 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic 5 percent crystalline amino acid solution
Number of subjects: 50
Study 808194 — intervention group
Group type: COMPARATOR
Intervention: Dextrose in water
Number of subjects: 50
Study 30779716 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 sets per muscle group per session (G5)
Number of subjects: 40
Study 30779716 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 sets per muscle group per session (G10)
Number of subjects: 40
Study 30779716 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 sets per muscle group per session (G15)
Number of subjects: 40
Study 30779716 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 sets per muscle group per session (G20)
Number of subjects: 40
Study 29320912 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-second auditory hallucination simulation
Number of subjects: 82
Study 25362103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 56
Study 24604289 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 Gy radiation therapy with 6 months of androgen-suppression therapy (AST)
Number of subjects: 206
Study 24604289 — intervention group
Group type: COMPARATOR
Intervention: 70 Gy radiation therapy without androgen-suppression therapy (AST)
Number of subjects: 206
Study 22648253 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin photodynamic therapy (PDT)
Number of subjects: 426
Study 22648253 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injections of bevacizumab (IVB)
Number of subjects: 426
Study 22648253 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpupillary thermotherapy (TTT)
Number of subjects: 426
Study 17598080 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser therapy
Number of subjects: 0
Study 17598080 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency obliteration
Number of subjects: 0
Study 17598080 — intervention group
Group type: COMPARATOR
Intervention: Classic varicose vein operation
Number of subjects: 0
Study 16290987 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (ABCX)
Number of subjects: 90
Study 16290987 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine (ADO)
Number of subjects: 90
Study 16290987 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 90
Study 12016080 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic magnetic resonance imaging of patellar tendinitis
Number of subjects: 51
Study 10354809 — intervention group
Group type: EXPERIMENTAL
Intervention: Movements made with elastic resistance
Number of subjects: 0
Study 10354809 — intervention group
Group type: COMPARATOR
Intervention: Movements made without elastic resistance
Number of subjects: 0
Study 8950959 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (S)
Number of subjects: 0
Study 8950959 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol (P)
Number of subjects: 0
Study 8950959 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (F)
Number of subjects: 0
Study 2103529 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical levobunolol treatment for four months
Number of subjects: 10
Study 2103529 — intervention group
Group type: COMPARATOR
Intervention: Untreated fellow eye (control)
Number of subjects: 10
Study 6122461 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 5
Study 6122461 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 5
Study 6122461 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline
Number of subjects: 5
Study 30802271 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-conception lifestyle intervention (n = 84)
Number of subjects: 178
Study 30802271 — intervention group
Group type: COMPARATOR
Intervention: Prompt infertility treatment (Control group, n = 94)
Number of subjects: 178
Study 28917215 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Project M (intervention)
Number of subjects: 74
Study 28917215 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 74
Study 25879244 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory electrical stimulation (AES)
Number of subjects: 28
Study 25879244 — intervention group
Group type: COMPARATOR
Intervention: Placebo electrical stimulation (PES)
Number of subjects: 28
Study 25879244 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual Inhibition (RI) group
Number of subjects: 28
Study 25879244 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresidual Inhibition (NRI) group
Number of subjects: 28
Study 24325609 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment group
Number of subjects: 0
Study 24325609 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 22291112 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cefixime for 10 days
Number of subjects: 171
Study 22291112 — intervention group
Group type: COMPARATOR
Intervention: Sequential intravenous ceftriaxone for 4 days followed by oral cefixime for 6 days
Number of subjects: 171
Study 19468040 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 0
Study 19468040 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived social support
Number of subjects: 0
Study 19468040 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived barriers
Number of subjects: 0
Study 19468040 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity measurement
Number of subjects: 0
Study 17484939 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioculturally tailored collaborative care intervention
Number of subjects: 446
Study 17484939 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 446
Study 15821197 — intervention group
Group type: EXPERIMENTAL
Intervention: AM3 (3 g/d for 180 days)
Number of subjects: 253
Study 15821197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 12688144 — intervention group
Group type: EXPERIMENTAL
Intervention: LNGB with cuff fixation (n1-GB+C)
Number of subjects: 691
Study 12688144 — intervention group
Group type: COMPARATOR
Intervention: LNGB without cuff fixation (n2-GB-C)
Number of subjects: 691
Study 9655770 — intervention group
Group type: EXPERIMENTAL
Intervention: LBPP at 25 mmHg
Number of subjects: 8
Study 9655770 — intervention group
Group type: EXPERIMENTAL
Intervention: LBPP at 50 mmHg
Number of subjects: 8
Study 9655770 — intervention group
Group type: EXPERIMENTAL
Intervention: LBPP at 75 mmHg
Number of subjects: 8
Study 9655770 — intervention group
Group type: EXPERIMENTAL
Intervention: LBPP at 25 mmHg during exercise
Number of subjects: 8
Study 9655770 — intervention group
Group type: EXPERIMENTAL
Intervention: LBPP at 50 mmHg during exercise
Number of subjects: 8
Study 9655770 — intervention group
Group type: EXPERIMENTAL
Intervention: LBPP at 75 mmHg during exercise
Number of subjects: 8
Study 7654486 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg twice daily
Number of subjects: 42
Study 7654486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 2653765 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril + hydrochlorothiazide (HCT)
Number of subjects: 116
Study 2653765 — intervention group
Group type: COMPARATOR
Intervention: Digoxin + hydrochlorothiazide (HCT)
Number of subjects: 116
Study 388401 — intervention group
Group type: EXPERIMENTAL
Intervention: tienilic acid (mean dose 210 mg)
Number of subjects: 38
Study 388401 — intervention group
Group type: COMPARATOR
Intervention: cyclopenthiazide (as control)
Number of subjects: 38
Study 388401 — intervention group
Group type: EXPERIMENTAL
Intervention: tienilic acid (mean daily dose of 184 mg)
Number of subjects: 38
Study 31947040 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz repetitive Transcranial Magnetic Stimulation (rTMS) four times a week for 3 weeks, 20 minutes per session
Number of subjects: 4
Study 31947040 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 4
Study 31947040 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz repetitive Transcranial Magnetic Stimulation (rTMS)
Number of subjects: 4
Study 28785906 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D titanium miniplate
Number of subjects: 40
Study 28785906 — intervention group
Group type: COMPARATOR
Intervention: Locking plate
Number of subjects: 40
Study 25229268 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza A(H1N1)pnd09 vaccination during pregnancy
Number of subjects: 488
Study 25229268 — intervention group
Group type: COMPARATOR
Intervention: Influenza A(H1N1)pnd09 vaccination after pregnancy
Number of subjects: 488
Study 22856533 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat supplementation
Number of subjects: 910
Study 22856533 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk supplementation
Number of subjects: 910
Study 22856533 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain traditional vegetable stew (githeri)
Number of subjects: 910
Study 22856533 — intervention group
Group type: COMPARATOR
Intervention: Control group (no snack)
Number of subjects: 910